British professor makes ‘thrilling’ breakthrough for cancer that killed his mother | Cancer research
PRugsor Paul Warckman was thirty -seven years old, and he was already firmly as a medical researcher when his mother, Ein, died due to rare bone cancer known as red tumor. About one in every million people is affected by the condition, which cannot be treated.
“It was completely frustrated,” said the worker, who later became the head of the center. cancer Discovery of drugs and then CEO of the Cancer Research Institute, London. “Thirty -six years ago, there was little that we could do to treat rope tumor. There was little understanding of the disease and no medications were available to help my mother.”
This dark condition can be close to change. The worker and colleagues, who work as part of international cooperation, have recently identified a major protein, known as Brachyury, who realized it was crucial for the survival of erythrocyte cells in the patient’s body.
This discovery caused great excitement among researchers because it suggested a way to attack insect tumor: prevent protein infection, and this would harm the cancer cells whose growth was strengthened. All that was required is a drug that can attack protein effectively.
The problem was the complex make -up of impossibility, which was considered drug resistance. However, in a A paper published in Nature Communications Last weekWorkman – with his colleagues in Oxford and North Carolina – revealed that after studying Brachyury with unprecedented details, they identified many sites on their surface that can be used as targets of specially designed drugs.
This penetration was achieved using one of the most powerful X -ray generators in the world: Diamond light source Synchrotron in Didcot, Oxfordshire.
As a result of this work, the Workman team has already managed to isolate many promising compounds that are now used to create potential treatments that can attack Brachyury and destroy protein. In this way, doctors may soon be able to treat papilloma, a condition that has so far resisted efforts to combat their growth and spread.
“It is fun to realize that I am helping to do something about the disease of killing my mother. Warckman said:” It took a great effort by many scientists from centers on both sides of the Atlantic, but it was worth it. “
It is important, that the techniques that are now developed to treat random limbs and lines have wider capabilities and can be used to improve treatments for other cancer more common, and the worker added. He added: “For the beginning of what, it seems that participation in the metastatic spread of other tumors, which means that medications that prevent their activities can also help in obstructing the spread of other cancers.”
The worker is the only child of John and Tomasina (Ena) worker. His father worked in the steel industry, while his mother was active in many community projects in their city, Workington, in Cumbria. He said: “My father died first, due to the intestinal cancer, many years before my mother surrendered to the tumor.”
Ena Workman’s diagnosis was complicated by the fact that she had suffered from severe back pain in most of her life: this could have caused her to diagnose – as the tumor of the cormon began at the base of its spine – in its early stages.
The worker said: “Brachyury plays a role in the fetus in promoting Notochord, an introduction to the spine,” the worker said. Then it is turned off after birth. However, in very few cases, it appears again, and when he does so, it can lead to wet tumor, as was the case with my mother. “
The same worker did not escape from the cancer diagnoses that affected his mother and father: In 2022, doctors told him that he had prostate cancer.
“This has helped to be a cancer, translated and small of intermediate risks and is likely to have a favorable result. The worker who successfully treated radiotherapy said:” I realize very well that many others have more difficult news in taking it. “
As for the types of medications that may one day be used to treat papilloma, the worker says that most hopes lie in a system called the deterioration of the targeted protein or TPD. This includes the process of cooperating the natural disposal system of the cell to remove the violating protein.
“Part of the drug is associated with the target protein, while the other part is participating directly with the systems of disposal of cell waste, which has shattered everything and expelled everything outside the cell.” “We will use the body’s special defenses to deal with Brachyury.”
This progress towards developing medicines to treat the nominal tumor took years and included a set of different advanced techniques. Regardless of the source of diamond light and the use of TPD techniques, a process known as examination of crystal fragments played a decisive role in highlighting the sites where medications can be abandoned with a ghost protein. The worker said: “This allowed us to develop the best medications that can reach the surface of the protein.”
However, the worker emphasized that more research is still necessary to master a drug that will be effective in treating strabomas. “We need to start experiments in the clinical tumor cell lines first and then in the sampling tumor models in animals before we start experiments in humans. This may take five years to complete it. Then, we hope that we will eventually be ready to face the challenge and pillar of peace.”
